• Prospectus & Reports
  • Close

    Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

    Your e-mail has been sent.

    Clicking a link will open a new window.
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Select Biotechnology Portfolio

  • Symbol: FBIOX
  • No Transaction Fee No Transaction Fee 1
  • Fidelity Fund Pick Fidelity Fund Pick

Fourth Quarter 2013 Summary

Strategy Review:

  • Select Biotechnology Portfolio is an industry-based, equity-focused strategy that seeks to outperform the benchmark through active management.
  • Fundamental, bottom-up research leveraging Fidelity's deep and experienced global health care team is the primary source of idea generation. Our analysis is driven by a data and statistical approach that places an emphasis on valuation through free cash flow and the probability risk-adjusted net present value of future cash flows.
  • Our investment approach includes evaluating a company's drug pipeline, the size of its market opportunity and its valuation relative to other opportunities. The fund's holdings center around the following four major investment themes: long-term winners and strong pipelines, turnaround companies, breakthrough innovations, and early-stage firms with promising science.
  • Sector strategies could be used by investors as alternatives to individual stocks for either tactical or strategic allocation purposes.
  • While this review mainly outlines drivers for the past quarter, our buy and sell decisions are typically based on the longer-term prospects for stocks and not on short time periods.

Sector Review:

  • For the three months ending December 31, 2013, the biotechnology industry returned 6.12%, as measured by the MSCI® U.S. IMI Biotechnology 25-50 Index, underperforming the broadly based S&P 500® Index, which returned 10.51%. A general industry sell-off to start the quarter put biotechnology stocks in a hole and, despite reversing the correction, they were not able to catch up with the broader market by quarter-end. A few of the more heavily weighted stocks in the index, such as Regeneron Pharmaceuticals, Vertex Pharmaceuticals and Amgen, which drove a large part of the industry's outperformance during 2013, were a drag on the group in the fourth quarter.
  • Despite early-stage companies receiving lofty valuations, the market continued to discipline those firms that reported regulatory obstacles and failed clinical trials. Additionally, a favorable regulatory environment thanks to new U.S. Food and Drug Administration legislation improved the pace for regulatory approval of novel drugs in areas of unmet needs.

Drivers of Fund Performance:

  • For the fourth quarter ending December 31, 2013, Select Biotechnology Portfolio returned 3.80%, underperforming the 6.12% advance of its sector benchmark, the MSCI® U.S. IMI Biotechnology 25-50 Index.
  • Negative stock selection drove the fund's relative underperformance during the period. The single largest detractor during the period was our overweighting of Stemline Therapeutics. Shares of the biotechnology company focused on cancer therapeutics lost more than half of their value in the fourth quarter. The company reported disappointing third-quarter financial results, which caused concern amongst investors who shied away from the stock after it surged 90% in the third quarter. We maintained our overweight position in Stemline as we believe it has a promising pipeline and is reasonably valued.
  • Elsewhere, a large overweight to Aegerion Pharmaceuticals was a drag on performance, as shares of the biopharmaceutical company focused on lipid disorders ended a volatile fourth quarter lower, despite reporting better-than-expected financial results from the third quarter. Investors sold shares of Aegerion after company management alluded that Wall Street was not factoring in enough operational expenses or the seasonality of its Juxtapid drug, as many patients decided to delay taking the drug until the beginning of 2014.
  • Timely trading of ARIAD Pharmaceuticals helped, as shares of the cancer-drug developer lost over half their value in early October after the company disclosed a higher-than-expected rate of circulatory blockages among patients using its leukemia drug, Iclusig®. The U.S. Food and Drug Administration placed a partial clinical hold on the drug, but the company will continue testing on a subset of patients shown to be at lower risk for blood clots. Our decision to increase our position in ARIAD following its decline proved beneficial, as shares began to rebound in the second half of the quarter.

End-Of-Quarter Positioning

  • We continue to be optimistic about the longer-term opportunity in biotechnology, where we believe advances in basic research and diagnostics tools, improved access to capital, and increased outsourcing of research and development by large pharmaceuticals companies provide tailwinds to the industry and drug development.
  • At quarter-end, we selectively overweighted large-cap companies, owing to reasonable valuations, new product cycles and undervalued drug pipelines. As the larger pharmaceuticals companies go through patent expirations, the larger biotechnology companies have become more-attractive acquisition targets. We also have positioned the fund to take advantage of select small- and mid-cap stocks that we believe have promising science.
  • The fund continued to emphasize a combination of attractively valued, cash-generative large-cap businesses with sound capital allocation practices, as well as several smaller- and mid-cap companies with emerging portfolios of drugs.

Finally, we remain committed to a disciplined investment process in pursuit of strong long-term results for our shareholders.

Fund Manager(s)

More Information
Rajiv Kaul since 10/12/2005

Strategy & Objective


Seeks capital appreciation.


Investing primarily in companies engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. Normally investing at least 80% of assets in securities of companies principally engaged in these activities. Normally investing primarily in common stocks.

Watch a brief video to learn about using the new mutual fund library to evaluate funds

The "Mutual Funds" area at the top of each page allows access to mutual fund holdings with individual and joint Fidelity non-retirement accounts. Individual stock positions, ETFs and 529 funds are not available through this view. For the full list of your holdings visit Portfolio Summary.

Mutual Funds are priced as of the previous business day's market close when the market is open. Mutual fund positions are priced as of the official market close (typically 4p.m.) and prices are generally available between 5 p.m. and 6p.m.

1. No Transaction Fee Fidelity funds are available without paying a trading fee to Fidelity or a sales load to the fund. However, the fund may charge a short-term trading or redemption fee to protect the interests of long-term shareholders of the fund. Shares are subject to the fund's management and operating expenses. See Expenses & Fees for more information.

Generally, data on Fidelity mutual funds is provided by FMR, LLC, Morningstar ratings and data on non-Fidelity mutual funds is provided by Morningstar, Inc. and data on non-mutual fund products is provided by the product's investment manager, trustee or issuer or the plan sponsor whose plan is offering the product to participants. Although Fidelity believes the data gathered from these third-party sources is reliable, it does not review such information and cannot warrant it to be accurate, complete or timely. Fidelity is not responsible for any damages or losses arising from any use of this third-party information.

Before investing, consider the investment objectives, risks, charges and expenses of the fund or annuity and its investment options. Contact Fidelity for a free prospectus and, if available, summary prospectus containing this information. Read it carefully.